Published in Health Business Week, November 3rd, 2006
In making this announcement at the annual meeting of shareholders, Claude LeDuc, president and CEO of BioSyntech, stated: "This achievement, which was made possible by our recent financing, marks another important milestone for BioSyntech. We have already assembled a team of highly talented and experienced executives and secured the financial resources to accomplish our objectives. In addition, we will be in the clinical stage with our three lead products before the end of the current fiscal year, and have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.